Answers are grounded in this paper and cite their sources.
INTRODUCTION: Neuropathic pain represents a difficult-to-treat chronic pain condition associated with complex molecular mechanisms and clinical heterogeneity. Although many pharmacologic treatments are available, current therapies often fail to deliver adequate analgesia. They are burdened with dose-limiting side effects, pointing to the need for more tolerable and efficacious non-opioid therapies. AREAS COVERED: This review presents recent advances in non-opioid analgesic development for neuropathic pain, focusing on emerging molecular targets, including ion channels and neuroimmune signaling, and innovative drug discovery approaches. Google Scholar was searched for relevant literature between 14 June 2026 and 19 October 2026. The review also discusses emerging therapeutic agents, translational challenges, and future directions in precision medicine and biomarker-guided drug development. EXPERT OPINION: While significant progress has been achieved in discovering new non-opioid therapeutic targets, clinical translation remains challenging because of high disease heterogeneity, low predictive value of traditional preclinical models, lack of biomarker implementation, and insufficient target validation. Future success will depend on prioritizing translationally relevant targets, integrating precision medicine and biomarker-driven patient selection, and employing advanced translational models and innovative technologies.
No takes yet. Share an insight, caveat, or question.
Sharma et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: